MedPath
HSA Approval

UFT CAPSULE

SIN03692P

UFT CAPSULE

UFT CAPSULE

September 22, 1989

PHARMAFORTE SINGAPORE PTE LTD

PHARMAFORTE SINGAPORE PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantPHARMAFORTE SINGAPORE PTE LTD
Licence HolderPHARMAFORTE SINGAPORE PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

CAPSULE

ORAL

Medical Information

L01BC53

tegafur, combinations

Manufacturer Information

PHARMAFORTE SINGAPORE PTE LTD

TAIHO PHARMACEUTICAL CO LTD

Active Ingredients

TEGAFUR

100 mg

Tegafur

URACIL

224 mg

Uracil

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

UFT CAPSULE - HSA Approval | MedPath